Pediatricians, Pediatric Specialist
33 years of experience
Video profile
Northwest Dallas
Children's Medical Center of Dallas
1935 Medical District Dr
Dallas, TX 75235
877-445-1234
Locations and availability (3)

Education ?

Medical School
Tulane University (1977)

Awards & Distinctions ?

Awards  
Best Doctors in America, 2005-2012
Board Member, American Board of Pediatrics, Sub-board of Pediatric Rheumatology
Texas Super Doctor (2007)
Texas Super Doctor (2006)
Immunex/ACR Visiting Pediatric Rheumatology Professor (2006)
Best Doctors in America (2007)
Castle Connolly's Top Doctors™ (2012 - 2013)
Associations
American College of Rheumatology
American Board of Pediatrics

Affiliations ?

Dr. Punaro is affiliated with 4 hospitals.

Hospital Affilations

Score

Rankings

  • UT Southwestern University Hospital - Zale Lipshy
    5151 Harry Hines Blvd, Dallas, TX 75235
    • Currently 4 of 4 crosses
    Top 25%
  • UT Southwestern University Hospital - St. Paul
    5909 Harry Hines Blvd, Dallas, TX 75235
    • Currently 4 of 4 crosses
    Top 25%
  • Children's Medical Center of Dallas *
    1935 Motor St, Dallas, TX 75235
    • Currently 4 of 4 crosses
    Top 25%
  • Texas Scottish Rite Hospital for Children *
    2222 Welborn St, Dallas, TX 75219
  • * This information was reported to Vitals by the doctor or doctor's office.

    Publications & Research

    Dr. Punaro has contributed to 6 publications.
    Title Treatment of Pediatric Localized Scleroderma: Results of a Survey of North American Pediatric Rheumatologists.
    Date April 2010
    Journal The Journal of Rheumatology
    Excerpt

    We surveyed pediatric rheumatologists (PR) in North America to learn how they treat pediatric localized scleroderma (LS), a disease associated with significant morbidity for the growing child.

    Title Congenital Localized Scleroderma.
    Date September 2006
    Journal The Journal of Pediatrics
    Excerpt

    OBJECTIVES: Juvenile localized scleroderma (JLS) usually has its onset during later childhood. This report describes the clinical and serologic features of six children with congenital localized scleroderma (CLS). STUDY DESIGN: A large, multinational study was conducted among pediatric rheumatology and dermatology centers by collecting information on demographics, family history, triggering environmental factors, clinical features, laboratory reports, and treatment of patients with JLS. Patients with onset at birth were carefully examined. RESULTS: Among 750 patients with JLS, 6 patients (0.8%) had scleroderma-related lesions at birth. Female-to-male ratio was 2:1. All patients had linear scleroderma, in four involving the face with en coup de sabre appearance. Two patients were misdiagnosed as having skin infection, one nevus, one salmon patch, and two undefined skin lesions. The mean diagnostic delay was 3.9 years. In comparison with the group of 733 patients with late-onset JLS, CLS presented a significantly more prolonged disease duration at diagnosis and a higher frequency of en coup de sabre subtypes. CONCLUSIONS: Congenital localized scleroderma is a rare and probably underestimated condition in neonates. The linear subtype was the exclusive manifestation of the disease. CLS should be included in the differential diagnosis of infants with cutaneous erythematous fibrotic lesions to avoid functional and aesthetic sequelae and to allow prompt therapy.

    Title Juvenile Localized Scleroderma: Clinical and Epidemiological Features in 750 Children. An International Study.
    Date June 2006
    Journal Rheumatology (oxford, England)
    Excerpt

    OBJECTIVE: Juvenile localized scleroderma (JLS) includes a number of conditions often grouped together. With the long-term goal of developing uniform classification criteria, we studied the epidemiological, clinical and immunological features of children with JLS followed by paediatric rheumatology and dermatology centres. METHODS: A large, multicentre, multinational study was conducted by collecting information on the demographics, family history, triggering environmental factors, clinical and laboratory features, and treatment of patients with JLS. RESULTS: Seven hundred and fifty patients with JLS from 70 centres were enrolled into the study. The disease duration at diagnosis was 18 months. Linear scleroderma (LS) was the most frequent subtype (65%), followed by plaque morphea (PM) (26%), generalized morphea (GM) (7%) and deep morphea (DM) (2%). As many as 15% of patients had a mixed subtype. Ninety-one patients (12%) had a positive family history for rheumatic or autoimmune diseases; 100 (13.3%) reported environmental events as possible trigger. ANA was positive in 42.3% of the patients, with a higher prevalence in the LS-DM subtype than in the PM-GM subtype. Scl70 was detected in the sera of 3% of the patients, anticentromere antibody in 2%, anti-double-stranded DNA in 4%, anti-cardiolipin antibody in 13% and rheumatoid factor in 16%. Methotrexate was the drug most frequently used, especially during the last 5 yr. CONCLUSION: This study represents the largest collection of patients with JLS ever reported. The insidious onset of the disease, the delay in diagnosis, the recognition of mixed subtype and the better definition of the other subtypes should influence our efforts in educating trainees and practitioners and help in developing a comprehensive classification system for this syndrome.

    Title The Impact on Health-related Quality of Life from Non-steroidal Anti-inflammatory Drugs, Methotrexate, or Steroids in Treatment for Juvenile Idiopathic Arthritis.
    Date May 2006
    Journal Journal of Pediatric Psychology
    Excerpt

    OBJECTIVE: To assess and compare the impact of medication treatments on health-related quality of life (HRQOL), family function, and medical status in children with juvenile idiopathic arthritis (JIA). METHODS: Fifty-seven children diagnosed with JIA were assessed by a pediatric rheumatologist and placed into one of three treatment groups: (1) non-steroidal anti-inflammatory; (2) methotrexate; or (3) steroids via IV methylprednisolone. Questionnaires were administered at baseline and 4-month follow-up. The attending pediatric rheumatologist provided additional medical information. RESULTS: Data document the impact of JIA on HRQOL, particularly on physical and pain domains. Steroid patients experienced improved HRQOL at follow-up relative to other groups, despite reporting more problems with side effects. CONCLUSION: These results demonstrate positive benefits of steroids in treating JIA children, despite the greatest incidence of adverse side effects.

    Title Common and Recurrent Hpgd Mutations in Caucasian Individuals with Primary Hypertrophic Osteoarthropathy.
    Date
    Journal Rheumatology (oxford, England)
    Excerpt

    Homozygous recessive germline mutations of the 15-hydroxyprostaglandin dehydrogenase (HPGD) gene, encoding 15-hydroxyprostaglandin dehydrogenase, result in persistent elevation of circulating PGE(2) levels, causing the syndrome of primary hypertrophic osteoarthropathy (PHO). Homozygous HPGD mutations have so far been reported in 10 families, all but one displaying parental consanguinity. Only two of these families were of European origin. We wished to determine the role of HPGD in causing PHO in non-consanguineous European families.

    Title The Lupus Family Registry and Repository.
    Date
    Journal Rheumatology (oxford, England)
    Excerpt

    The Lupus Family Registry and Repository (LFRR) was established with the goal of assembling and distributing materials and data from families with one or more living members diagnosed with SLE, in order to address SLE genetics. In the present article, we describe the problems and solutions of the registry design and biometric data gathering; the protocols implemented to guarantee data quality and protection of participant privacy and consent; and the establishment of a local and international network of collaborators. At the same time, we illustrate how the LFRR has enabled progress in lupus genetics research, answering old scientific questions while laying out new challenges in the elucidation of the biologic mechanisms that underlie disease pathogenesis. Trained staff ascertain SLE cases, unaffected family members and population-based controls, proceeding in compliance with the relevant laws and standards; participant consent and privacy are central to the LFRR's effort. Data, DNA, serum, plasma, peripheral blood and transformed B-cell lines are collected and stored, and subject to strict quality control and safety measures. Coded data and materials derived from the registry are available for approved scientific users. The LFRR has contributed to the discovery of most of the 37 genetic associations now known to contribute to lupus through 104 publications. The LFRR contains 2618 lupus cases from 1954 pedigrees that are being studied by 76 approved users and their collaborators. The registry includes difficult to obtain populations, such as multiplex pedigrees, minority patients and affected males, and constitutes the largest collection of lupus pedigrees in the world. The LFRR is a useful resource for the discovery and characterization of genetic associations in SLE.


    Similar doctors nearby

    Dr. Ashu Kumar

    Pediatric Emergency Medicine
    8 years experience
    Dallas, TX

    Dr. Colin Kane

    Internal Medicine
    8 years experience
    Dallas, TX

    Dr. Carla Garcia

    Pediatrics
    10 years experience
    Dallas, TX

    Dr. Elizabeth Persad

    Pediatrics
    9 years experience
    Dallas, TX

    Dr. Tiffany Simms-Waldrip

    Pediatrics
    6 years experience
    Dallas, TX

    Dr. William Engle

    Pediatrics
    36 years experience
    Dallas, TX
    Search All Similar Doctors